Analysts Conflicted on These Healthcare Names: Cartesian Therapeutics (RNAC), Insmed (INSM) and BioNTech SE (BNTX)
TipRanksApr 23 18:40
Insmed (INSM.US) was first covered by Truist Securities, which gave it a buy rating, with a target price of $48.00.
Zhitong FinanceApr 23 18:41
Insmed Analyst Ratings
BenzingaApr 23 18:39
Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and UnitedHealth (UNH)
TipRanksApr 17 01:20
Barclays: Maintaining the Insmed (INSM.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $37.00 to $40.00.
Zhitong FinanceApr 11 21:30
Insmed Analyst Ratings
BenzingaApr 11 21:26
Barclays Maintains Overweight on Insmed, Raises Price Target to $40
BenzingaApr 11 21:29
Insmed Analyst Ratings
BenzingaApr 1 23:59
Wells Fargo Maintains Overweight on Insmed, Maintains $55 Price Target
BenzingaApr 2 00:01
Analysts Are Bullish on Top Healthcare Stocks: Annexon Biosciences (ANNX), Insmed (INSM)
TipRanksApr 1 18:03
Strong Endorsement and Market Expansion Potential Justify Buy Rating for Insmed's Brensocatib
TipRanksMar 19 14:08
Analysts Conflicted on These Healthcare Names: Insmed (INSM), Oric Pharmaceuticals (ORIC) and CytomX Therapeutics (CTMX)
TipRanksMar 12 20:20
Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and Zimmer Biomet Holdings (ZBH)
TipRanksMar 7 20:30
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Insmed (INSM)
TipRanksMar 5 20:40
Buy Rating Affirmed for Insmed on Positive Pipeline Prospects and Robust Revenue Forecasts
TipRanksFeb 28 13:06
Insmed Analyst Ratings
BenzingaFeb 28 01:10
Insmed Analyst Ratings
BenzingaFeb 27 18:37
Buy Rating Affirmed for Insmed on Strong Sales and Promising Trial Outlook
TipRanksFeb 26 12:26
Barclays Sticks to Its Buy Rating for Insmed (INSM)
TipRanksFeb 23 16:16
Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and BioMarin Pharmaceutical (BMRN)
TipRanksFeb 23 11:50
No Data
No Data